Ependymal overexpression of brain-derived neurotrophic factor (BDNF) stimulates the addition of new medium spiny neurons to the adult neostriatum, from endogenous subependymal progenitor cells. Noggin, by suppressing subependymal gliogenesis, potentiates BDNF-induced neuronal recruitment. We asked if these agents might be used to stimulate striatal neurogenesis in R6/2 mice, a transgenic model of Huntington's Disease engineered to express a roughly 145 CAG repeat expansion in the first exon of the huntingtin gene. R6/2 or wild-type mice (n = 18 each) were given intraventricular injections of either AdBDNF/AdNoggin, AdBDNF, AdNull or saline, all at 6 weeks of age. All were then injected daily for 30 days with BrdU to tag new cells, the neurons among which were identified by labeling for βIII-tubulin, NeuN, GAD67 or DARPP-32. AdBDNF/AdNoggin-treated R6/2 mice showed substantial striatal neurogenesis (277.0 ± 52.7 BrdU+/βIII-tubulin+ neurons/mm3), significantly so compared to AdBDNF- (135.0 ± 34.1), AdNull- (20.1 ± 6.5) and saline- (5.1 ± 7.8) treated R6/2 mice (p<0.01 by ANOVA). Moreover, the number of new neurons in the AdBDNF/AdNoggin-treated R6/2 striatum did not differ significantly from that of AdBDNF/AdNoggin-treated wild-type controls (219.9 ± 19.4/mm3), indicating that R6/2 mice were as able as wild-types to mount a neurogenic response to treatment. Saline and AdNull-treated R6/2 mice, but not their wild-type controls, also exhibited striatal neuronal addition, indicating a degree of compensatory neurogenesis in R6/2 mice. The new neurons were recruited largely as DARPP-32+/GAD67+ GABAergic medium spiny cells, and Fluorogold injections confirmed that they extended fibers to the globus pallidus. Rotarod testing revealed that AdBDNF/AdNoggin-treated R6/2 mice exhibited both a delayed and decelerated progression of motor impairment, relative to AdNull-injected R6/2 mice. Thus, ependymal overexpression of BDNF and noggin induced the recruitment of substantial numbers of new GABAergic medium spiny projection neurons to the R6/2 huntingtin transgenic neostriatum, and this was associated with a slower onset of motor impairment in affected animals. These data suggest the feasibility of directed neuronal regeneration as a therapeutic option in Huntington's disease.
Read full abstract